

Supplementary Online Content

Nelson CA, Zhong CS, Hashemi DA, et al. A multicenter cross-sectional study and systematic review of necrobiotic xanthogranuloma with proposed diagnostic criteria. *JAMA Dermatology*. Published online January 15, 2020.
doi:10.1001/jamadermatol.2019.4221

eTable. Systematic Review of the Demographics, Comorbidities, and Clinical Features of Necrobiotic Xanthogranuloma
eReferences.

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Systematic Review of the Demographics, Comorbidities, and Clinical Features of Necrobiotic Xanthogranuloma

Al-Bermani et al. ¹ , 2009	47	F	W	IgG kappa	Red or pink papules on the extremities.	Pain	Eye		L			
Al-Niaimi et al. ² , 2010	42	M			Yellow or orange atrophic plaques on the face.	None			NL	No		
AlGain et al. ³ , 2017	81	M		IgG kappa, MM	Yellow or orange papules on the face, trunk, and extremities.		Gastrointestinal tract		L			
Ali et al. ⁴ , 2012	59	M		IgG lambda	Yellow or orange papules on the extremities.		Eye	H	NL			
Amer et al. ⁵ , 2005	31	F		IgG kappa	Plaques in a periorbital distribution.		Eye and liver					
Bain et al. ⁶ , 2014	78	M		IgG kappa, MM	Purple indurated papule on the extremities.	None						
Balagula et al. ⁷ , 2011	77	M		IgM, Waldenstrom macroglobulinemia	Red or pink indurated plaques on the extremities.							
Barzilai et al. ⁸ , 1996	85	F		IgG kappa	Purple atrophic plaques on the face, trunk, and extremities.	None						
Betts et al. ⁹ , 2001	58	M	W	IgG lambda	Red or pink ulcerated papules and nodules on the extremities.							
Bhari et al. ¹⁰ , 2015	75	M		IgG kappa	Red or pink atrophic plaques on the face, trunk, and extremities.							
Bortolani et al. ¹¹ , 1999	72	F	W	IgG kappa, MM	Yellow or orange nodules in a periorbital distribution.							
Bullock et al. ¹² , 1986	57	F	W	IgG kappa, MM	Yellow or orange indurated nodules in a periorbital distribution.		Eye					
Burdick et al. ¹³ , 2003	57	F	W*	IgG kappa	Red or pink plaques with telangiectasias on the face, trunk, and extremities.							
Butterfield et al. ¹⁴ , 1994	47	F	W	Polyclonal, lymphoma	Yellow or orange indurated nodules in a periorbital distribution.		Lymphoreticular system and parotid gland	NL				

Carabelli et al. ¹⁵ , 1997	70	F		IgG lambda, MM	Yellow or orange indurated ulcerated papules in a periorbital distribution and on the trunk and extremities.					Yes	
Chandra et al. ¹⁶ , 2002	32	F			Red or pink atrophic plaque with telangiectasias on the extremities.			NL	NL	No	
Chang et al. ¹⁷ , 2003	82	F	A		Brown single nodule with telangiectasia on the extremities.	None		NL	NL	No	
Char et al. ¹⁸ , 1987	63	F		Unspecified paraproteinemia	Purple nodules in a periorbital distribution and on the extremities.				L	Yes	
Chave et al. ¹⁹ , 2001	66	F		IgG kappa	Yellow or orange plaques in a periorbital distribution and on the trunk.			NL	NL	No	
Chave et al. ²⁰ , 2001	75	M		IgG lambda	Brown atrophic ulcerated plaques with telangiectasias on the trunk and extremities.			NL			
Chen et al. ²¹ , 2011	68	M		IgG kappa, leukemia			Lymphoreticular system		NL		
Codere et al. ²² , 1983	52	M		IgG kappa	Yellow or orange plaques with telangiectasias in a periorbital distribution and on the trunk and extremities.					Yes	
	56	F		IgG kappa	Plaques in a periorbital distribution and elsewhere on the face.	None	Eye				
Cornblath et al. ²³ , 1992	45	M		IgG kappa, leukemia	Plaques on the face, trunk, and extremities.						
	64	F		IgG kappa	Ulcerated plaques in a periorbital distribution and on the trunk and extremities.		Eye			Yes	
	59	F		IgG lambda	Yellow or orange plaques in a periorbital distribution and elsewhere on the face.						
	70	F		IgG kappa	Plaques in a periorbital distribution and on the trunk and extremities.						
Criado et al. ²⁴ , 2002	40	F	W	IgG lambda	Yellow or orange atrophic ulcerated plaques with telangiectasias in a periorbital distribution and on the trunk and extremities.				NL	No	
Criton et al. ²⁵ , 1996	57	F		Unspecified paraproteinemia	Brown plaques in a periorbital distribution and elsewhere on the face and the extremities.			NL			

Dabiri et al. ²⁶ , 2011	83	M		IgG lambda	Red or pink plaques in a periorbital distribution and on the trunk and extremities.	Pruritus						
Davies et al. ²⁷ , 2017	50	M		IgG kappa, lymphoma	Yellow or orange ulcerated plaques in a periorbital distribution.		Eye					
	75	F		Unspecified paraproteinemia	Ulcerated plaques in a periorbital distribution.		Eye					
	24	M			Plaque in a periorbital distribution.		Eye					
	73	M			Plaque in a periorbital distribution.		Eye					
DeLuca et al. ²⁸ , 2014	89	F	W	IgG kappa	Yellow or orange ulcerated plaques on the trunk and extremities.							
Dholaria et al. ²⁹ , 2016	51	M	W	IgG lambda, MM	Red or pink ulcerated plaques on the trunk and extremities.							
Dilnawaz, ³⁰ 2010	73	F	W	IgG lambda	Red or pink atrophic plaques on the trunk and extremities.						Yes	
Dupre et al. ³¹ , 1988	60	F			Yellow or orange indurated plaques on the extremities.	None		H				
Efebera et al. ³² , 2011	79	M	W	IgG kappa, MM	Red or pink ulcerated plaques on the trunk and extremities.	Pain						
Elner et al. ³³ , 2006	60	M			Yellow or orange nodules in a periorbital distribution.		Eye					
	54	M		Lymphoma	Yellow or orange nodules in a periorbital distribution.		Eye					
	73	F		Unspecified paraproteinemia	Yellow or orange nodules in a periorbital distribution.	Pain	Eye					
	41	M		Unspecified paraproteinemia, lymphoma	Yellow or orange nodules in a periorbital distribution.		Eye					
Esmaeli et al. ³⁴ , 2017	47	F		Polyclonal	Yellow or orange indurated plaques in a periorbital distribution and on the trunk.			NL	NL			
Ferrara et al. ³⁵ , 2007	81	F		IgG kappa	Yellow or orange indurated plaque on the extremities.							
Finelli et al. ³⁶ , 1987	50	F	W	IgG kappa	Yellow or orange ulcerated plaques on the extremities.			NL	NL	No		
Fink et al. ³⁷ , 2018	75	M	W	Lymphoma	Brown plaques in a periorbital distribution and on the trunk.	Pain						
Flann et al. ³⁸ , 2006	58	M		IgG kappa	Purple nodules on the face, trunk, and extremities.							

	52	M			Red or pink plaques on the face, trunk, and extremities.						
	68	F		IgG kappa, leukemia	Plaques on the face, trunk, and extremities.	Pruritus		H			
	86	M		IgG kappa	Purple ulcerated plaques on the trunk and extremities.						
Fortson et al. ³⁹ , 1990	78	M	W	IgA	Yellow or orange papules on the face and trunk.	Pain	Gastrointestinal tract	NL		No	
Fu et al. ⁴⁰ , 2011	73	F	A	IgG kappa, lung adenocarcinoma	Yellow or orange nodules on the trunk and extremities.	None					
Furner et al. ⁴¹ , 1989	63	M		IgG kappa	Brown atrophic, ulcerated papules on the face, trunk, and extremities.						
Gacto et al. ⁴² , 2009	50	F		IgG kappa	Yellow or orange plaques in a periorbital distribution and on the trunk.	Pruritus					
	55	F			Yellow or orange nodules in a periorbital distribution.	None					
Georgiou et al. ⁴³ , 1999	82	M	W		Yellow or orange atrophic plaques with telangiectasias on the trunk.	None		NL			
Gergen et al. ⁴⁴ , 2011	56	M		IgG kappa, lymphoma	Yellow or orange nodules with telangiectasias on the trunk and extremities.	None					
Ghani et al. ⁴⁵ , 2013	46	F		IgG kappa	Yellow or orange papules in a periorbital distribution.						
Ghiasi et al. ⁴⁶ , 2012	58	M		Polyclonal	Red or pink ulcerated plaques on the trunk and the extremities.	Pain		NL			
Girisha et al. ⁴⁷ , 2012	61	F			Yellow or orange plaques in a periorbital distribution.	Pruritus		NL			
Goede et al. ⁴⁸ , 2007	26	M		IgG kappa	Yellow or orange plaques in a periorbital distribution and on the trunk.						
Gonzales et al. ⁴⁹ , 2017	36	F	W	IgG kappa	Yellow or orange indurated ulcerated plaques in a periorbital distribution and on the trunk.		Eye				
Goyal et al. ⁵⁰ , 2018	42	F	A	IgG kappa	Purple plaques in a periorbital distribution.	Pain			L	Yes	
Gun et al. ⁵¹ , 2004	44	F			Red or pink plaques with telangiectasias within a scar.	Pain			NL	No	

Hallerman et al. ⁵² , 2010	55	F	W	IgG lambda	Red or pink indurated plaques on the face, trunk, and extremities.						
	69	F	W	IgG kappa, MM	Red or pink plaques on the face, trunk, and extremities.	None					
Hamilton et al. ⁵³ , 2014	63	F	W	IgG lambda, leukemia	Brown plaques on the face and trunk.						
Hashemi et al. ⁵⁴ , 2012	58	F	W	IgG kappa	Purple nodules on the trunk.		Eye				
Hauser et al. ⁵⁵ , 1991	57	M		IgG kappa	Yellow or orange plaques on the face, trunk, and extremities.						
Herd et al. ⁵⁶ , 2018	40	M		Unspecified paraproteinemia, lymphoma	Yellow or orange plaques with telangiectasias on the trunk and extremities, including within a scar.						
Holden et al. ⁵⁷ , 1986	78	F		IgG kappa	Yellow or orange atrophic plaques with telangiectasias in a periorbital distribution and on the trunk.			NL	NL	No	
	64	F		IgG kappa	Purple atrophic ulcerated plaques with telangiectasias in a periorbital distribution and elsewhere on the face and trunk.			NL		No	
	55	F		IgG kappa	Yellow or orange atrophic ulcerated plaques with telangiectasias in a periorbital distribution and on the trunk, including within a scar.			NL		No	
	85	F		IgG kappa	Yellow or orange atrophic ulcerated nodules in a periorbital distribution and on the extremities.	Pain		N		No	
Hunter et al. ⁵⁸ , 1985	39	F	W	IgG kappa	Yellow or orange ulcerated nodules with telangiectasias in a periorbital distribution and elsewhere on the face and extremities.		Gastrointestinal tract and heart				
Inthasotti et al. ⁵⁹ , 2011	64	F		IgG lambda, MM	Yellow or orange atrophic ulcerated plaques in a periorbital distribution and on the extremities.	None					
Ito et al. ⁶⁰ , 2008	86	F		IgG lambda	Brown atrophic plaques on the extremities.				NL		
Jeziorska et al. ⁶¹ , 2003	65	F		IgG kappa	Yellow or orange plaques in a periorbital distribution and on the trunk.						

	55	F		IgG kappa	Yellow or orange plaques in a periorbital distribution and elsewhere on the face and trunk.	Pain		NL			
Johnston et al. ⁶² , 1997	69	F		IgG kappa	Red or pink atrophic plaques with telangiectasias on the trunk and extremities.	Pruritus			L	No	
Kadokia et al. ⁶³ , 2012	65	F			Brown atrophic nodules with telangiectasias in a periorbital distribution.	None					
Kawakami et al. ⁶⁴ , 2011	93	F	A	IgG lambda	Yellow or orange plaque on the extremities.	Pain					
Keorochana et al. ⁶⁵ , 2017	53	M	A	Polyclonal			Eye	H			
Khan et al. ⁶⁶ , 2009	54	F	W	IgG lambda	Yellow or orange plaques in a periorbital distribution.						
Khan et al. ⁶⁷ , 2012	82	F	W		Red or pink nodule on the trunk.	None			NL	No	
Koch et al. ⁶⁸ , 2008	77	F		IgG kappa	Yellow or orange ulcerated plaques on the trunk and extremities.	Pain		NL			
Koch et al. ⁶⁹ , 2013	79	F		IgG kappa	Yellow or orange plaques on the trunk and extremities, including within a scar.	None					
Kossard et al. ⁷⁰ , 2000	88	M		IgG kappa	Yellow or orange ulcerated nodules on the face, trunk, and extremities.						
Kovalyshyn et al. ⁷¹ , 2009	82	F		IgG kappa	Purple plaques in a periorbital distribution and on the trunk and extremities.						
Kunikata et al. ⁷² , 2006	65	F	A		Yellow or orange nodule on the face.				H	No	
Lam et al. ⁷³ , 2013	78	M		IgG kappa, MM	Yellow or orange plaques in a periorbital distribution.	None					
Langlois et al. ⁷⁴ , 2006	75	F	W	IgG lambda, MM	Yellow or orange plaques in a periorbital distribution and on the trunk and extremities.				L		
Le et al. ⁷⁵ , 1997	67	M	W	IgG kappa	Yellow or orange atrophic ulcerated plaques in a periorbital distribution and on the trunk and extremities.	Pain			NL		

Lebey et al. ^{76,77} , 1997**	88	F	W	IgG kappa	Purple plaques with telangiectasias in a periorbital distribution and on the trunk and extremities.	None			L		
Lee et al. ⁷⁸ , 2017	44	M		IgG kappa	Brown plaques on the extremities.						
Li et al. ⁷⁹ , 2014	50	F			Yellow or orange plaques with telangiectasias in a periorbital distribution.			NL	NL	No	
Liszewski et al. ⁸⁰ , 2014	39	F	W		Red or pink plaques on the face and trunk.						
	60	F		IgG kappa	Red or pink plaques in a periorbital distribution and on the trunk and extremities.						
Luck et al. ⁸¹ , 1992	42	F		IgG kappa	Yellow or orange plaques in a periorbital distribution.						
Lukacs et al. ⁸² , 2017	74	F	W	IgM	Red or pink ulcerated plaques in a periorbital distribution and on the extremities.						
Macfarlane et al. ⁸³ , 1985	66	M		IgG kappa	Purple nodules in a periorbital distribution and on the trunk and extremities.	Pain		NL	L	No	
McGregor et al. ⁸⁴ , 1993	73	M	W	IgG kappa	Red or pink Ulcerated nodules on the trunk and extremities.						
	76	M		IgG lambda	Ulcerated plaques on the trunk and extremities.	None					
Machado et al. ⁸⁵ , 2001	51	F	W	IgG lambda	Purple nodules with telangiectasias in a periorbital distribution and on the trunk and extremities.	None			L	Yes	
Mahendran et al. ⁸⁶ , 2018	78	F	W	IgG kappa, MM	Yellow or orange plaques in a periorbital distribution.				L		
Martinez Fernandez et al. ⁸⁷ , 2004	73	M		IgG kappa, MM	Brown plaques in a periorbital distribution.			NL	L	No	
Mathias et al. ⁸⁸ , 2011	61	F			Yellow or orange papules in a periorbital distribution.	None					
Matsuura et al. ⁸⁹ , 1999	76	M		IgG lambda	Yellow or orange ulcerated nodules in a periorbital distribution and on the extremities.			NL			

Meyer et al. ⁹⁰ , 2005	53	F		IgG kappa	Yellow or orange indurated plaques in a periorbital distribution.	Pain	Eye				
Minocha et al. ⁹¹ , 2017	57	M		IgG kappa	Yellow or orange papules in a periorbital distribution and on the trunk.				NL	No	
	63	F		IgG lambda	Brown nodules in a periorbital distribution and on the trunk and extremities.		Eye				
Miszkiel et al. ⁹² , 2000	52	M			Yellow or orange plaques in a periorbital distribution.		Eye				
Mohsenin et al. ⁹³ , 2012	53	M		Unspecified paraproteinemia, lymphoma	Yellow or orange multiple lesions in a periorbital distribution.	Pain	Eye				
Muscardin et al. ⁹⁴ , 2003	40	M		Polyclonal	Brown papules on the trunk and extremities.						
Naghshpour et al. ⁹⁵ , 2011	52	F		IgG lambda, leukemia	Yellow or orange nodules in a periorbital distribution and elsewhere on the face.	Pain					
Nestle et al. ⁹⁶ , 1999	77	F		IgG lambda	Yellow or orange nodules in a periorbital distribution and on the trunk and extremities.						
Nishimura et al. ⁹⁷ , 1992	67	M		IgG kappa	Purple plaques in a periorbital distribution and on the trunk.				L		
Nockowski et al. ⁹⁸ , 2017	83	F		IgG kappa	Yellow or orange ulcerated nodules in a periorbital distribution and on the trunk.						
Novak et al. ⁹⁹ , 1992	73	F		IgG kappa	Ulcerated plaques on the face, trunk, and extremities.		Heart and liver				
Oestreicher et al. ¹⁰⁰ , 2010	95	F			Yellow or orange ulcerated plaques in a periorbital distribution.		Eye				
Olson et al. ¹⁰¹ , 2018	44	F	W	IgG kappa, MM	Yellow or orange plaques in a periorbital distribution.	Pain			L	Yes	
Omarjee et al. ¹⁰² , 2018	64	F		IgM, leukemia	Yellow or orange nodules on the extremities.						
Oumeish et al. ¹⁰³ , 2006	56	F		IgG kappa, lymphoma	Yellow or orange ulcerated plaques in a periorbital distribution and on the trunk and extremities.	Pain and pruritus					

Pedrosa et al. ¹⁰⁴ , 2015	44	F	W	IgG kappa	Purple indurated plaques in a periorbital distribution and on the extremities.	None						
Peyman et al. ¹⁰⁵ , 2012	57	M		IgG lambda	Yellow or orange atrophic plaques on the trunk and extremities.		Eye					
Plotnick et al. ¹⁰⁶ , 1991	40	F	W	IgG kappa, MM	Nodules in a periorbital distribution.	None		NL				
Randell et al. ¹⁰⁷ , 1999	51	F		IgG lambda	Yellow or orange nodules in a periorbital distribution.			NL				
Rashid et al. ¹⁰⁸ , 2009	70	F		Unspecified paraproteinemia	Yellow or orange plaques in a periorbital distribution.	Pruritus						
Rayner et al. ¹⁰⁹ , 2008	76	F	W	IgG kappa	Nodule on the trunk and extremities, including within a scar.		Liver and lung					
Reddy et al. ¹¹⁰ , 2010	73	F		Unspecified paraproteinemia, MM	Yellow or orange plaques in a periorbital distribution.		Eye					
Reeder et al. ¹¹¹ , 1991	20	F		Polyclonal, lymphoma	Atrophic plaques with telangiectasias on the extremities.					No		
Rose et al. ¹¹² , 1991	22	M	W	IgG kappa	Yellow or orange plaques in a periorbital distribution.	None	Eye	NL	L			
	50	M	W	Unspecified paraproteinemia, lymphoma	Yellow or orange plaques in a periorbital distribution.		Eye					
Rose et al. ¹¹³ , 2012	63	F		Unspecified paraproteinemia	Yellow or orange plaques with telangiectasias on the face, trunk, and extremities.							
Rubinstein et al. ¹¹⁴ , 2013	68	F		IgG kappa	Yellow or orange nodules on the face, trunk, and extremities.							
Russo et al. ¹¹⁵ , 2002	68	M		IgG lambda	Yellow or orange indurated plaques on the trunk and extremities.				NL	Yes		
Ryan et al. ¹¹⁶ , 2012	55	M		IgG lambda, leukemia	Yellow or orange indurated plaques on the trunk and extremities.							
Saeki et al. ¹¹⁷ , 2007	57	F	A	IgG kappa	Red or pink ulcerated nodules with telangiectasias in a periorbital distribution and on the extremities.				L	No		
Sagiv et al. ¹¹⁸ , 2018	61	M			Yellow or orange plaques in a periorbital distribution.							

Santosaputri et al. ¹¹⁹ , 2014	51	F		IgG kappa	Yellow or orange and purple plaques and nodules on the face and trunk, including within a scar.		Liver				
Schaudig et al. ¹²⁰ , 2004	67	F	W	IgG kappa	Red or pink ulcerated plaques on the face, trunk, and extremities.						
Scupham et al. ¹²¹ , 1989	57	F		IgG kappa	Yellow or orange plaques in a periorbital distribution and on the extremities.	Pain			L		
Seastrom et al. ¹²² , 2014	76	M			Yellow or orange indurated plaques in a periorbital distribution.			NL			
Sfeir et al. ¹²³ , 2017	83	F		IgG lambda, breast cancer	Yellow or orange plaques on the face, trunk, and extremities.						L [^]
Shah et al. ¹²⁴ , 2004	52	M			Nodules in a periorbital distribution and on the trunk and extremities.	None	Brain and eye				
Silapunt et al. ¹²⁵ , 2010	81	M	W	IgG kappa	Brown nodules in a periorbital distribution and on the trunk and extremities.	Pruritus		NL			
Singh et al. ¹²⁶ , 2010	67	M	W	IgG kappa	Plaques in a periorbital distribution.						
	62	F	W								
Smith et al. ¹²⁷ , 2006	61	F		IgG kappa	Yellow or orange nodule with telangiectasias on the trunk.	None					
Stork et al. ¹²⁸ , 2000	60	F	W		Brown plaque on the extremities.	None		L	NL	No	
Sutton et al. ¹²⁹ , 2013	71	M		IgG lambda	Yellow or orange ulcerated plaques on the face, trunk, and extremities.				L		
Szalat et al. ¹³⁰ , 2011	67	F		IgG kappa, MM						No	
	65	F		IgG kappa, MM						No	
	63	M		IgG lambda						No	
	71	F		IgG lambda							
	72	F		IgG kappa					L	No	
	48	M		IgG kappa, lymphoma					L		
	53	M		IgG kappa							
	65	F		IgG kappa, MM						No	
	78	F		IgG kappa							
	65	F		IgG lambda, MM							

	68	F		IgG kappa							
Szalat et al. ¹³¹ , 2014	68	M		IgG lambda	Multiple lesions on the face, trunk, and extremities.			L	L		
	69	F		IgG kappa, MM	Multiple lesions on the face, trunk, and extremities.			NL	L		
	65	F		IgG kappa	Multiple lesions in a periorbital distribution.				L		
	68	F		IgG kappa, MM	Multiple lesions on the trunk.			L	L		
	65	F		IgG lambda	Multiple lesions on the trunk.			L	L		
	60	M		IgG lambda	Multiple lesions in a periorbital distribution.			NL	L		
	73	F		IgG lambda, MM	Multiple lesions in a periorbital distribution.			L			
	83	F		IgG kappa, MM	Multiple lesions on the face, trunk, and extremities.			L			
Torabian et al. ¹³² , 2006	56	M		IgG lambda	Red or pink atrophic ulcerated plaques with telangiectasias in a periorbital distribution and on the trunk and extremities.	Pruritus			L		
Tucker et al. ¹³³ , 1997	43	F			Yellow or orange nodules in a periorbital distribution.		Eye				
Umbert et al. ¹³⁴ , 1995	61	F		IgG kappa	Yellow or orange plaques in a periorbital distribution and elsewhere on the face and trunk.		Heart and lymphoreticular system			Yes	
Valentine et al. ¹³⁵ , 1990	64	M	W	IgA, MM, rectal cancer	Nodule in a periorbital distribution.	None					
Venencie et al. ¹³⁶ , 1987	46	M		IgG kappa, MM	Yellow or orange nodules in a periorbital distribution and on the trunk and extremities.				NL		
Venencie et al. ¹³⁷ , 1995	65	F	W	IgG kappa	Yellow or orange nodules in a periorbital distribution and on the trunk and extremities.						
Vieira et al. ¹³⁸ , 2005	68	F		IgG lambda, lymphoma	Brown plaques in a periorbital distribution and on the trunk.						
Vignon et al. ¹³⁹ , 2017	65	F		IgG kappa, MM	Nodules on the trunk.	Pain and pruritus					
	66	M		IgG kappa			Eye				

Vu et al. ¹⁴⁰ , 2017	55	M	W	IgG kappa	Yellow or orange ulcerated nodule in a periorbital distribution and on the trunk.		Eye		L	No	
Wee et al. ¹⁴¹ , 2005	67	M	W	Unspecified paraproteinemia	Brown papules on the face and extremities.						
Wei et al. ¹⁴² , 2015	69	M	A		Brown atrophic plaques with telangiectasias on the extremities.			NL		No	
Wells et al. ¹⁴³ , 2004	53	F		IgG kappa	Yellow or orange plaques in a periorbital distribution and on the extremities.	Pruritus					
Winkelmann et al. ¹⁴⁴ , 1997	47	M		IgG lambda	Yellow or orange plaques in a periorbital distribution and on the trunk.						
	64	M		IgG kappa	Red or pink atrophic plaques and nodules on the trunk and extremities.		Gastrointestinal tract and lung	L	L		
	39	F		Unspecified paraproteinemia	Yellow or orange plaque on the extremities.		Heart and lung				
Wolz et al. ¹⁴⁵ , 2012	64	M		IgM kappa	Red or pink ulcerated papules on the extremities.	Pain			L		
Wruhs et al. ¹⁴⁶ , 2016	82	F		IgG lambda	Red or pink atrophic plaques on the trunk.						
Yang et al. ¹⁴⁷ , 2010	46	M	A	IgG kappa	Red or pink ulcerated papules on the trunk and extremities.			NL	L	No	
Yasukawa et al. ¹⁴⁸ , 2005	69	F	A	IgG kappa	Yellow or orange atrophic plaques on the trunk and extremities.		Muscle				
Yoon et al. ¹⁴⁹ , 2007	66	F		IgG kappa, MM	Brown indurated nodules on the extremities.	None					
Zainal et al. ¹⁵⁰ , 2010	48	M	A				Parotid gland				
Zelger et al. ^{151,152} , *** 2007	55	M		IgG lambda	Atrophic plaques on the face, trunk, and extremities.						
	37	F		IgG kappa	Yellow or orange plaques on the face, trunk, and extremities.						
	70	M			Plaques on the face and trunk.						
	42	F			Plaques on the face.						
	49	F		IgG kappa	Plaques in a periorbital distribution and elsewhere on the face and trunk.						
	63	F		IgG kappa	Plaques in a periorbital distribution.						

	56	F		IgM	Plaques in a periorbital distribution and on the trunk and extremities.						
Ziemer et al. ¹⁵³ , 2012	55	F		IgG lambda	Brown indurated plaques in a periorbital distribution and on the trunk and extremities.						

* Patient identified as Hispanic or Latino ethnicity.

^ Patient had a high 1,25-dihydroxyvitamin D level

**The associated reference was accidentally duplicated.

***These references refer to the same patient. Reference 151 is included in the article; reference 152 is omitted.

A, Asian; C, complement; cryos, cryoglobulins; F, female; H, high; HDL-C, high-density lipoprotein cholesterol; Ig, immunoglobulin; L, low; M, male; MM, multiple myeloma; NL, normal; VD, 25-hydroxyvitamin D; W, White

eReferences

1. Al-Bermani A, Figueiredo F, Speight EL, Jackson GH, Pandit R. Necrobiotic xanthogranuloma masquerading as posterior scleritis. *Eye (London, England)*. 2009;23(1):239-240.
2. Al-Niaimi FA, Dawn G, Cox NH. Necrobiotic xanthogranuloma without paraproteinaemia: marked improvement with psoralen ultraviolet A treatment. *Clinical and experimental dermatology*. 2010;35(3):275-277.
3. AlGain M, Szalat R, Vignon-Pennamen MD, et al. A rare case of disseminated skin and mucosal necrobiotic xanthogranuloma and xanthoma. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2017;31(1):e3-e5.
4. Ali FR, Green R, Chularojanamontri L, Young HS, Motta L. Recurrent posterior scleritis and a 'sebaceous cyst': Extrafacial necrobiotic xanthogranuloma. *British Journal of Dermatology*. 2012;167:18-19.
5. Amer R, Pe'er J, Pappo O, Dotan S. Necrobiotic xanthogranuloma associated with choroidal infiltration and syncytial giant cell hepatitis. *Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society*. 2005;25(3):189-192.
6. Bain EE, 3rd, Meehan SA, Hale EK. Solitary necrobiotic xanthogranuloma of an upper extremity in association with multiple myeloma. *Journal of drugs in dermatology : JDD*. 2014;13(5):598-600.
7. Balagula Y, Straus DJ, Pulitzer MP, Lacouture ME. Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenstrom macroglobulinemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(11):e305-307.
8. Barzilai A, Trau H, Shpiro D, Yorav S. Necrobiotic xanthogranuloma with paraproteinemia. *Cutis*. 1996;57(5):320-322.
9. Betts CM, Pasquinelli G, Costa AM, Fanti PA, Misciali C, Varotti C. Necrobiotic xanthogranuloma without periorbital involvement: an ultrastructural investigation. *Ultrastructural pathology*. 2001;25(6):437-444.
10. Bhari N, Chiramel MJ, VEDI KK, et al. Necrobiotic xanthogranuloma with multiple myeloma. *Clinical and experimental dermatology*. 2015;40(7):811-814.
11. Bortolani A, Barisoni D, Bontempini L. Necrobiotic xanthogranuloma of the eyelids with paraproteinemia. *European Journal of Plastic Surgery*. 1999;22(1):36-39.
12. Bullock JD, Bartley GB, Campbell RJ, Yanes B, Connelly PJ, Funkhouser JW. Necrobiotic xanthogranuloma with paraproteinemia: case report and a pathogenetic theory. *Transactions of the American Ophthalmological Society*. 1986;84:342-354.
13. Burdick AE, Sanchez J, Elgart GW. Necrobiotic xanthogranuloma associated with a benign monoclonal gammopathy. *Cutis*. 2003;72(1):47-50.
14. Butterfield JH, Bartley GB. Atypical periorbital xanthogranulomas associated with systemic benign lymphoepithelial lesions. *Ophthalmic plastic and reconstructive surgery*. 1994;10(4):287-292.
15. Carabelli A, Cecca E, Crovetto G, et al. IgG lambda multiple myeloma and diffuse necrobiotic xanthogranuloma association: A case report. *European Journal of Dermatology*. 1997;7(7):519-521.

16. Chandra S, Finklestein E, Gill D. Necrobiotic xanthogranuloma occurring within linear morphoea. *The Australasian journal of dermatology*. 2002;43(1):52-54.
17. Chang SE, Lee WS, Lee MW, et al. A case of necrobiotic xanthogranuloma without paraproteinemia presenting as a solitary tumor on the thigh. *International journal of dermatology*. 2003;42(6):470-472.
18. Char DH, LeBoit PE, Ljung BM, Wara W. Radiation therapy for ocular necrobiotic xanthogranuloma. *Archives of ophthalmology (Chicago, Ill : 1960)*. 1987;105(2):174-175.
19. Chave TA, Chowdhury MM, Holt PJ. Recalcitrant necrobiotic xanthogranuloma responding to pulsed high-dose oral dexamethasone plus maintenance therapy with oral prednisolone. *The British journal of dermatology*. 2001;144(1):158-161.
20. Chave TA, Hutchinson PE. Necrobiotic xanthogranuloma with two monoclonal paraproteins and no periorbital involvement at presentation. *Clinical and experimental dermatology*. 2001;26(6):493-496.
21. Chen KY, Leslie W, Mahon B, Venugopal P. A patient with necrobiotic xanthogranuloma presenting with an anterior mediastinal mass, plasma cell dyscrasia, and a lymphoproliferative disorder. *Clinical advances in hematology & oncology : H&O*. 2011;9(9):696-700.
22. Codere F, Lee RD, Anderson RL. Necrobiotic xanthogranuloma of the eyelid. *Archives of ophthalmology (Chicago, Ill : 1960)*. 1983;101(1):60-63.
23. Cornblath WT, Dotan SA, Trobe JD, Headington JT. Varied clinical spectrum of necrobiotic xanthogranuloma. *Ophthalmology*. 1992;99(1):103-107.
24. Criado PR, Vasconcellos C, Pegas JR, et al. Necrobiotic xanthogranuloma with lambda paraproteinemia: case report of successful treatment with melphalan and prednisone. *The Journal of dermatological treatment*. 2002;13(2):87-89.
25. Criton S, Asokan PU, Pailey S, Kuttappan SS, Rodriguez FP. Necrobiotic xanthogranuloma with paraproteinaemia. *Indian journal of dermatology, venereology and leprology*. 1996;62(6):383-385.
26. Dabiri S, Morales A, Ma L, et al. The frequency of dual TCR-PCR clonality in granulomatous disorders. *Journal of cutaneous pathology*. 2011;38(9):704-709.
27. Davies MJ, Whitehead K, Quagliotto G, Wood D, Patheja RS, Sullivan TJ. Adult Orbital and Adnexal Xanthogranulomatous Disease. *Asia-Pac J Ophthalmol*. 2017;6(5):435-443.
28. DeLuca IJ, Grossman ME. Vulvar necrobiotic xanthogranuloma. *Journal of the American Academy of Dermatology*. 2014;71(6):e247-248.
29. Dholaria BR, Cappel M, Roy V. Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone. *Annals of hematology*. 2016;95(4):671-672.
30. Dilnawaz M. An unusual skin presentation of necrobiotic xanthogranuloma. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*. 2010;20(4):274-275.
31. Dupre A, Viraben R. Necrobiotic xanthogranuloma: a case without paraproteinemia but with transepithelial elimination. *Journal of cutaneous pathology*. 1988;15(2):116-119.
32. Efebera Y, Blanchard E, Allam C, Han A, Lee S, Munshi N. Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. *Clinical lymphoma, myeloma & leukemia*. 2011;11(3):298-302.

33. Elner VM, Mintz R, Demirci H, Hassan AS. Local corticosteroid treatment of eyelid and orbital xanthogranuloma. *Ophthalmic plastic and reconstructive surgery*. 2006;22(1):36-40.
34. Esmaeli N, Ghanadan A, Mansouri P, Ghaedi F. Necrobiotic xanthogranuloma after penicillin injection: A case report. *Iranian Journal of Dermatology*. 2017;20(1):26-28.
35. Ferrara G, Palombi N, Lipizzi A, Zalaudek I, Argenziano G. Nonnecrobiotic necrobiotic xanthogranuloma. *The American Journal of dermatopathology*. 2007;29(3):306-308.
36. Finelli LG, Ratz JL. Plasmapheresis, a treatment modality for necrobiotic xanthogranuloma. *Journal of the American Academy of Dermatology*. 1987;17(2 Pt 2):351-354.
37. Fink C, Schneiderbauer R, Hartschuh W, Enk A, Toberer F. Necrobiotic xanthogranuloma associated with chronic lymphocytic leukemia. *International journal of dermatology*. 2018;57(6):719-720.
38. Flann S, Wain EM, Halpern S, Andrews V, Whittaker S. Necrobiotic xanthogranuloma with paraproteinaemia. *Clinical and experimental dermatology*. 2006;31(2):248-251.
39. Fortson JS, Schroeter AL. Necrobiotic xanthogranuloma with IgA paraproteinemia and extracutaneous involvement. *The American Journal of dermatopathology*. 1990;12(6):579-584.
40. Fu T, Zwerner J, Kim J, Tang J. Subcutaneous nodules in an elderly patient. Necrobiotic xanthogranuloma. *Archives of dermatology*. 2011;147(10):1215-1220.
41. Furner BB, Stevens CS. Diffuse, ulcerating plaques and nodules. Necrobiotic xanthogranuloma (NXG) with paraproteinemia. *Archives of dermatology*. 1989;125(2):287-288, 290.
42. Gacto P, Barrera F, Pereyra JJ, Fernandez-Ortega P. Necrobiotic xanthogranuloma: efficacy of surgery in 2 patients. *Actas dermo-sifiliograficas*. 2009;100(6):499-502.
43. Georgiou S, Monastirli A, Kapranos N, Pasmatzis E, Sakkis T, Tsambaos D. Interferon alpha-2a monotherapy for necrobiotic xanthogranuloma. *Acta dermato-venereologica*. 1999;79(6):484-485.
44. Gergen N, Biebl K, Berg BC, Suwattee P. Slowly growing yellow nodules: challenge. Necrobiotic xanthogranuloma. *The American Journal of dermatopathology*. 2011;33(1):92-93, 103-104.
45. Ghani S, Al Ustwani O, Khalid B, et al. Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy. *Clinical advances in hematology & oncology : H&O*. 2013;11(10):678-680.
46. Ghiasi N, Alavi A, Coutts PM, Ghazarian D, Sibbald RG. Necrobiotic xanthogranuloma as an unusual cause of refractive chronic bilateral leg ulceration. *The international journal of lower extremity wounds*. 2012;11(4):293-295.
47. Girisha BS, Holla AP, Fernandes M, Noronha TM. Necrobiotic xanthogranuloma. *Journal of cutaneous and aesthetic surgery*. 2012;5(1):43-45.
48. Goede JS, Misselwitz B, Taverna C, et al. Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation. *Annals of hematology*. 2007;86(4):303-306.
49. Gonzales JA, Haemel A, Gross AJ, Acharya NR. Management of Uveitis and Scleritis in Necrobiotic Xanthogranuloma. *Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics*. 2017;33(4):325-333.

50. Goyal A, O'Leary D, Vercellotti G, Miller D, McGlave P. Intravenous immunoglobulin for treatment of necrobiotic xanthogranuloma. *Dermatologic therapy*. 2018:e12744.
51. Gun D, Demircay Z, Demirkesen C. Necrobiotic xanthogranuloma in a burn scar. *International journal of dermatology*. 2004;43(4):293-295.
52. Hallermann C, Tittelbach J, Norgauer J, Ziemer M. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. *Archives of dermatology*. 2010;146(9):957-960.
53. Hamilton HK, Dover JS, Arndt KA. Successful treatment of disfiguring hemosiderin-containing hyperpigmentation with the Q-switched 650-nm wavelength laser. *JAMA dermatology*. 2014;150(11):1221-1222.
54. Hashemi P, Rashidi A, Chapas AM, Balfour EM. Necrobiotic xanthogranuloma of the extremities with paraproteinemia and without periorbital involvement at presentation. *Cutis*. 2012;89(1):41-44.
55. Hauser C, Schifferli J, Saurat JH. Complement consumption in a patient with necrobiotic xanthogranuloma and paraproteinemia. *Journal of the American Academy of Dermatology*. 1991;24(5 Pt 2):908-911.
56. Herd TJ, Fischer R, Christensen LC, Rajpara A. Irregular yellow-brown plaques on the trunk and thighs. *Cutis*. 2018;101(1):12;15.
57. Holden CA, Winkelmann RK, Wilson Jones E. Necrobiotic xanthogranuloma: a report of four cases. *The British journal of dermatology*. 1986;114(2):241-250.
58. Hunter L, Burry AF. Necrobiotic xanthogranuloma: a systemic disease with paraproteinemia. *Pathology*. 1985;17(3):533-536.
59. Inthasotti S, Wanitphakdeedecha R, Manonukul J. A 7-Year History of Necrobiotic Xanthogranuloma following Asymptomatic Multiple Myeloma: A Case Report. *Dermatology research and practice*. 2011;2011:927852.
60. Ito Y, Nishimura K, Yamanaka K, et al. Necrobiotic xanthogranuloma with paraproteinemia; an atypical case. *Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG*. 2008;6(1):40-43.
61. Jeziorska M, Hassan A, Mackness MI, et al. Clinical, biochemical, and immunohistochemical features of necrobiotic xanthogranulomatosis. *Journal of clinical pathology*. 2003;56(1):64-68.
62. Johnston KA, Grimwood RE, Meffert JJ, Deering KC. Necrobiotic xanthogranuloma with paraproteinemia: an evolving presentation. *Cutis*. 1997;59(6):333-336.
63. Kadakia S, Nadkarni N, Sonavane S, Ghate S. Spectacular skin nodules: cutaneous necrobiotic xanthogranuloma without paraproteinemia. *Indian journal of dermatology*. 2012;57(5):396-398.
64. Kawakami Y, Yamamoto T. Letter: Necrobiotic xanthogranuloma of extremities in an elderly patient successfully treated with low-dose prednisolone. *Dermatology online journal*. 2011;17(6):13.
65. Keorochana N, Klanarongran K, Satayasootorn K, Chaiamnuay S. Necrobiotic xanthogranuloma scleritis in a case of granulomatosis with polyangiitis (Wegener's granulomatosis). *International medical case reports journal*. 2017;10:323-328.
66. Khan IJ, Azam NA, Sullivan SC, Habboush HW, Christian A. Necrobiotic xanthogranuloma successfully treated with a combination of dexamethasone and oral cyclophosphamide. *Canadian journal of ophthalmology Journal canadien d'ophtalmologie*. 2009;44(3):335-336.

67. Khan M, Ahmed I, Carr R. An unusual subcutaneous lump. *Clinical and experimental dermatology*. 2012;37(7):808-810.
68. Koch D, Lucas G, Durrington P, Lear JT. Ulcerating necrobiotic xanthogranulomata and paraproteinaemia treated with thalidomide. *British Journal of Dermatology*. 2008;159:16-17.
69. Koch PS, Goerdts S, Geraud C. Erythematous papules, plaques, and nodular lesions on the trunk and within preexisting scars. *JAMA dermatology*. 2013;149(9):1103-1104.
70. Kossard S, Chow E, Wilkinson B, Killingsworth M. Lipid and giant cell poor necrobiotic xanthogranuloma. *Journal of cutaneous pathology*. 2000;27(7):374-378.
71. Kovalyshyn I, Busam KJ, Marghoob AA. Orange-yellow diffuse cutaneous eruption in an 82-year-old woman. *Archives of dermatology*. 2009;145(10):1183+1188.
72. Kunikata N, Kikuchi K, Hashimoto A, Tagami H. Necrobiotic xanthogranuloma of the nose without paraproteinemia. *The Journal of dermatology*. 2006;33(11):809-812.
73. Lam K, Brownstein S, Jordan DR, van der Jagt R, Jastrzebski A, Dionne MA. Bilateral necrobiotic xanthogranuloma of the eyelids followed by a diagnosis of multiple myeloma 20 years later. *Ophthalmic plastic and reconstructive surgery*. 2013;29(5):e119-120.
74. Langlois S, Brochot P, Reguiat Z, et al. Necrobiotic xanthogranuloma with multiple myeloma. Case report and pathogenic hypotheses. *Joint, bone, spine : revue du rhumatisme*. 2006;73(1):120-122.
75. Le AV, Fenske NA. An unusual granulomatous disease in the elderly - Necrobiotic xanthogranuloma (NXG) with paraproteinemia. *Archives of dermatology*. 1997;133(10):1303-&.
76. Lebey PB, Determer I, Bazex J, el Sayed F, Marguery MC. Periorbital papules and nodules. Necrobiotic xanthogranuloma. *Archives of dermatology*. 1997;133(1):99, 102.
77. Lebey PB, Determer I, Bazex J, ElSayed F, Marguery MC. Periorbital papules and nodules. *Archives of dermatology*. 1997;133(1):98-&.
78. Lee HJ, Kim JM, Kim GW, et al. Necrobiotic xanthogranuloma treated with a combination of oral methylprednisolone and cyclosporin. *The Journal of dermatology*. 2017;44(10):1190-1191.
79. Li S, Chen AJ, Fang S, Li H. Successful treatment of necrobiotic xanthogranuloma with total glucosides of paeony. *Dermatologic therapy*. 2014;27(5):304-306.
80. Liszewski W, Wisniewski JD, Safah H, Boh EE. Treatment of refractory necrobiotic xanthogranulomas with extracorporeal photopheresis and intravenous immunoglobulin. *Dermatologic therapy*. 2014;27(5):268-271.
81. Luck J, Layton A, Noble BA. Necrobiotic xanthogranuloma with orbital involvement. *Journal of the Royal Society of Medicine*. 1992;85(6):357-358.
82. Lukacs J, Goetze S, Elsner P. Periocular Necrobiotic Xanthogranuloma Successfully Treated with Intravenous Immunoglobulin. *Acta dermato-venereologica*. 2017;97(6):754-755.
83. Macfarlane AW, Verbov JL. Necrobiotic xanthogranuloma with paraproteinaemia. *The British journal of dermatology*. 1985;113(3):339-343.
84. McGregor JM, Miller J, Smith NP, Hay RJ. Necrobiotic xanthogranuloma without periorbital lesions. *Journal of the American Academy of Dermatology*. 1993;29(3):466-469.

85. Machado S, Alves R, Lima M, Leal I, Massa A. Cutaneous necrobiotic xanthogranuloma (NXG)--successfully treated with low dose chlorambucil. *European journal of dermatology : EJD*. 2001;11(5):458-462.
86. Mahendran P, Wee J, Chong H, Natkunarajah J. Necrobiotic xanthogranuloma treated with lenalidomide. *Clinical and experimental dermatology*. 2018;43(3):345-347.
87. Martinez Fernandez M, Rodriguez Prieto MA, Ruiz Gonzalez I, Sanchez Sambucety P, Delgado Vicente S. Necrobiotic xanthogranuloma associated with myeloma. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2004;18(3):328-331.
88. Mathias M, Permi HS, Shetty P, Jayaprakash Shetty K, Girish BS. Necrobiotic xanthogranuloma presenting as a clinical variant without paraproteinemia. *Nitte University Journal of Health Science*. 2011;1(1-3):72-74.
89. Matsuura F, Yamashita S, Hirano K, et al. Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia--a possible pathogenesis of necrobiotic xanthogranuloma. *Atherosclerosis*. 1999;142(2):355-365.
90. Meyer S, Szeimies RM, Landthaler M, Hohenleutner S. Cyclophosphamide-dexamethasone pulsed therapy for treatment of recalcitrant necrobiotic xanthogranuloma with paraproteinemia and ocular involvement. *The British journal of dermatology*. 2005;153(2):443-445.
91. Minocha R, Lee S, Choi JYJ, Mann S. Necrobiotic xanthogranuloma: A report of two fascinating cases. *Hong Kong Journal of Dermatology and Venereology*. 2017;25(2):84-89.
92. Miszkiel KA, Sohaib SAA, Rose GE, Cree IA, Moseley IF. Radiological and clinicopathological features of orbital xanthogranuloma. *British Journal of Ophthalmology*. 2000;84(3):251-258.
93. Mohsenin A, Sinard J, Huang JJ. Necrobiotic xanthogranuloma and chronic lymphocytic leukemia of the conjunctiva masquerading as scleritis and uveitis. *Clinical ophthalmology (Auckland, NZ)*. 2012;6:2045-2047.
94. Muscardin LM, Mastroianni A, Chistolini A, Pulsoni A. Necrobiotic xanthogranuloma without periorbital lesions and without paraproteinaemia. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2003;17(2):233-235.
95. Naghashpour M, Setoodeh R, Moscinski L, et al. Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjogren syndrome. *The American Journal of dermatopathology*. 2011;33(8):855-857.
96. Nestle FO, Hofbauer G, Burg G. Necrobiotic xanthogranuloma with monoclonal gammopathy of the IgG lambda type. *Dermatology (Basel, Switzerland)*. 1999;198(4):434-435.
97. Nishimura M, Takano-Nishimura Y, Yano I, Hayashi N, Toshitani S. Necrobiotic xanthogranuloma in a human T-lymphotropic virus type 1 carrier. *Journal of the American Academy of Dermatology*. 1992;27(5 Pt 2):886-889.
98. Nockowski P, Wozniak Z, Reich A, Maj J. Xanthoma-like Skin Changes in an Elderly Woman with a Normal Lipid Profile. *Acta dermatovenerologica Croatica : ADC*. 2017;25(2):167-169.

99. Novak PM, Robbins TO, Winkelmann RK. Necrobiotic xanthogranuloma with myocardial lesions and nodular transformation of the liver. *Human pathology*. 1992;23(2):195-196.
100. Oestreicher J, Dookeran R, Nijhawan N, Kolin A. Necrobiotic xanthogranuloma with predominant periorbital involvement. *Ophthalmic plastic and reconstructive surgery*. 2010;26(6):473-475.
101. Olson RM, Harrison AR, Maltry A, Mokhtarzadeh A. Periorbital Necrobiotic Xanthogranuloma Successfully Treated with Intravenous Immunoglobulin. *Case reports in ophthalmology*. 2018;9(1):70-75.
102. Omarjee L, Janin A, Etienne G, et al. Necrobiotic xanthogranuloma: a paraneoplastic skin lesion of haematological malignancies? *European journal of dermatology : EJD*. 2018;28(3):384-386.
103. Oumeish OY, Oumeish I, Tarawneh M, Salman T, Sharaiha A. Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. *International journal of dermatology*. 2006;45(3):306-310.
104. Pedrosa AF, Ferreira O, Calistru A, et al. Necrobiotic xanthogranuloma with giant cell hepatitis, successfully treated with intravenous immunoglobulins. *Dermatologic therapy*. 2015;28(2):68-70.
105. Peyman A, Walsh N, Green P, Dorey MW, Seamone C, Pasternak S. Necrobiotic xanthogranuloma associated with necrotizing scleritis. *The American Journal of dermatopathology*. 2012;34(6):644-647.
106. Plotnick H, Taniguchi Y, Hashimoto K, Negendank W, Tranchida L. Periorbital necrobiotic xanthogranuloma and stage I multiple myeloma. Ultrastructure and response to pulsed dexamethasone documented by magnetic resonance imaging. *Journal of the American Academy of Dermatology*. 1991;25(2 Pt 2):373-377.
107. Randell PL, Heenan PJ. Necrobiotic xanthogranuloma with paraproteinaemia. *The Australasian journal of dermatology*. 1999;40(2):114-115.
108. Rashid MM, Chowdhury T, Sultana A, Begum R, Islam S, Ahmed I. Necrobiotic xanthogranuloma - A case report. *Journal of Pakistan Association of Dermatologists*. 2009;19(3):175-177.
109. Rayner SA, Duncombe AS, Keefe M, Theaker J, Manners RM. Necrobiotic xanthogranuloma occurring in an eyelid scar. *Orbit (Amsterdam, Netherlands)*. 2008;27(3):191-194.
110. Reddy VC, Salomao DR, Garrity JA, Baratz KH, Patel SV. Periorbital and ocular necrobiotic xanthogranuloma leading to perforation. *Archives of ophthalmology (Chicago, Ill : 1960)*. 2010;128(11):1493-1494.
111. Reeder CB, Connolly SM, Winkelmann RK. The evolution of Hodgkin's disease and necrobiotic xanthogranuloma syndrome. *Mayo Clinic proceedings*. 1991;66(12):1222-1224.
112. Rose GE, Patel BC, Garner A, Wright JE. Orbital xanthogranuloma in adults. *The British journal of ophthalmology*. 1991;75(11):680-684.
113. Rose A, Robinson M, Kamino H, Latkowski JA. Necrobiotic xanthogranuloma. *Dermatology online journal*. 2012;18(12):30.

114. Rubinstein A, Wolf DJ, Granstein RD. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. *Journal of cutaneous medicine and surgery*. 2013;17(5):347-350.
115. Russo GG. Necrobiotic xanthogranuloma with scleroderma. *Cutis*. 2002;70(6):311-316.
116. Ryan E, Warren LJ, Szabo F. Necrobiotic xanthogranuloma: response to chlorambucil. *The Australasian journal of dermatology*. 2012;53(2):e23-25.
117. Saeki H, Tomita M, Kai H, et al. Necrobiotic xanthogranuloma with paraproteinemia successfully treated with melphalan, prednisolone and skin graft. *The Journal of dermatology*. 2007;34(11):795-797.
118. Sagiv O, Thakar SD, Morrell G, Tetzlaff MT, Esmaeli B. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. *Ophthalmic plastic and reconstructive surgery*. 2018;34(1):e24-e27.
119. Santosaputri E, Ellis EJ, Nagiah S, Chrispal A, Thomas A. A multisystem granulomatous disease: necrobiotic xanthogranuloma with hepatic involvement. *The Medical journal of Australia*. 2014;200(8):490-493.
120. Schaudig U, Al-Samir K. Upper and lower eyelid reconstruction for severe disfiguring necrobiotic xanthogranuloma. *Orbit (Amsterdam, Netherlands)*. 2004;23(1):65-76.
121. Scupham RK, Fretzin DF. Necrobiotic xanthogranuloma with paraproteinemia. *Archives of pathology & laboratory medicine*. 1989;113(12):1389-1391.
122. Seastrom S, Bookout A, Hogan DJ. Necrobiotic xanthogranuloma without a monoclonal gammopathy. *Cutis*. 2014;94(6):293-296.
123. Sfeir JG, Zogala RJ, Popii VB. Hypercalcemia in Necrobiotic Xanthogranuloma: First Reported Case and Insight Into Treatment. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2017;32(4):784-787.
124. Shah KC, Poonnoose SI, George R, Jacob M, Rajshekhar V. Necrobiotic xanthogranuloma with cutaneous and cerebral manifestations. Case report and review of the literature. *Journal of neurosurgery*. 2004;100(6):1111-1114.
125. Silapunt S, Chon SY. Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide. *Journal of drugs in dermatology : JDD*. 2010;9(3):273-276.
126. Singh K, Rajan KD, Eberhart C. Orbital necrobiotic xanthogranuloma associated with systemic IgG4 disease. *Ocular immunology and inflammation*. 2010;18(5):373-378.
127. Smith HG, Sargent LA, Lundgrin DB. Necrobiotic xanthogranuloma of the chest wall. *Dermatology online journal*. 2006;12(1):12.
128. Stork J, Kodetova D, Vosmik F, Krejca M. Necrobiotic xanthogranuloma presenting as a solitary tumor. *The American Journal of dermatopathology*. 2000;22(5):453-456.
129. Sutton L, Sutton S, Sutton M. Treatment of necrobiotic xanthogranuloma with 2-chlorodeoxyadenosine. *Skinmed*. 2013;11(2):121-123.
130. Szalat R, Arnulf B, Karlin L, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. *Blood*. 2011;118(14):3777-3784.
131. Szalat R, Pirault J, Femand JP, et al. Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy. *Journal of internal medicine*. 2014;276(3):269-284.
132. Torabian SZ, Fazel N, Knuttle R. Necrobiotic xanthogranuloma treated with chlorambucil. *Dermatology online journal*. 2006;12(5):11.

133. Tucker NA, Discepolo MJ, Blanco G, Burnier MN, Jr. Necrobiotic xanthogranuloma without dermatologic involvement. *Canadian journal of ophthalmology Journal canadien d'ophtalmologie*. 1997;32(6):396-399.
134. Umberto I, Winkelmann RK. Necrobiotic xanthogranuloma with cardiac involvement. *The British journal of dermatology*. 1995;133(3):438-443.
135. Valentine EA, Friedman HD, Zamkoff KW, Streeten BW. Necrobiotic xanthogranuloma with IgA multiple myeloma: a case report and literature review. *American journal of hematology*. 1990;35(4):283-285.
136. Venencie PY, Puissant A, Verola O, et al. Necrobiotic xanthogranuloma with myeloma. A case report. *Cancer*. 1987;59(3):588-592.
137. Venencie PY, Le Bras P, Toan ND, Tchernia G, Delfraissy JF. Recombinant interferon alfa-2b treatment of necrobiotic xanthogranuloma with paraproteinemia. *Journal of the American Academy of Dermatology*. 1995;32(4):666-667.
138. Vieira V, Del Pozo J, Martinez W, Veiga-Barreiro JA, Fonseca E. Necrobiotic xanthogranuloma associated with lymphoplasmacytic lymphoma. Palliative treatment with carbon dioxide laser. *European journal of dermatology : EJD*. 2005;15(3):182-185.
139. Vignon M, Placais L, Malphettes M, et al. Non-cirrhotic portal hypertension in necrobiotic xanthogranuloma associated with monoclonal gammopathy. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2017;31(9):e403-e405.
140. Vu K, Gupta R, Frater J, Atkinson J, Ranganathan P. A 55-Year-Old Man With Periorbital and Inguinal Masses, Pericarditis, and Pleuritis. *Arthritis Care and Research*. 2017;69(5):730-736.
141. Wee SA, Shupack JL. Necrobiotic xanthogranuloma. *Dermatology online journal*. 2005;11(4):24.
142. Wei YH, Cheng JJ, Wu YH, et al. Necrobiotic xanthogranuloma: response to dapsone. *Dermatologic therapy*. 2015;28(1):7-9.
143. Wells J, Gillespie R, Zardawi I. Case of recalcitrant necrobiotic xanthogranuloma. *The Australasian journal of dermatology*. 2004;45(4):213-215.
144. Winkelmann RK, Litzow MR, Umberto IJ, Lie JT. Giant cell granulomatous pulmonary and myocardial lesions in necrobiotic xanthogranuloma with paraproteinemia. *Mayo Clinic proceedings*. 1997;72(11):1028-1033.
145. Wolz M, Peters MS. Necrobiotic xanthogranuloma of the extremities. *Journal of drugs in dermatology : JDD*. 2012;11(1):122-123.
146. Wruhs M, Feldmann R, Sawetz I, Breier F, Steiner A. Necrobiotic Xanthogranuloma in a Patient with Multiple Myeloma. *Case reports in dermatology*. 2016;8(3):350-353.
147. Yang CY, Chung WH, Rosaline CYH, Kuo TT, Yang CH. Necrobiotic xanthogranuloma with paraproteinemia without periorbital involvement - A case report. *Dermatologica Sinica*. 2010;28(3):125-129.
148. Yasukawa K, Kato N, Hamasaka A, Hata H. Necrobiotic xanthogranuloma: isolated skeletal muscle involvement and unusual changes. *Journal of the American Academy of Dermatology*. 2005;52(4):729-731.
149. Yoon SY, Park HJ, Lee JY, Cho BK. Necrobiotic xanthogranuloma with multiple myeloma and no periorbital involvement. *Ann Dermatol*. 2007;19(1):22-24.
150. Zainal A, Razif MY, Makhshen M, Swaminathan M, Mazita A. Necrobiotic xanthogranuloma of the parotid gland. *The Journal of laryngology and otology*. 2010;124(5):569-571.

151. Zelger B, Eisendle K, Mensing C, Zelger B. Detection of spirochetal micro-organisms by focus-floating microscopy in necrobiotic xanthogranuloma. *Journal of the American Academy of Dermatology*. 2007;57(6):1026-1030.
152. Ziemer M, Wedding U, Sander CS, Elsner P. Necrobiotic xanthogranuloma-rapid progression under treatment with melphalan. *European journal of dermatology : EJD*. 2005;15(5):363-365.
153. Ziemer M, Norgauer J, Simon JC, Koehler MJ. An unusual histologic variant of necrobiotic xanthogranuloma. *The American Journal of dermatopathology*. 2012;34(2):e22-26.